References
- Khardori R. Diabetes mellitus, type 2. Available from: http://emedicine.medscape.com/article/117853-overview [Last accessed at 16 October 2014]
- Seino Y, Yape D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Invest 2013;4:108-30
- Calanna S, Christensen M, Holst JJ, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia 2013;56:965-72
- Calanna S, Christensen M, Holst JJ, et al. Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies. Diabetes Care 2013;36:3346-52
- Doggrell SA. Exenatide extended-release: clinical trials, patient preference, and economic considerations. Patient Prefer Adherence 2013;7:1-11
- Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728-42
- Ahrén B, Johnson SL, Stewart M, et al. HARMONY 3: 104-Week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 3 diabetes taking metformin. Diabetes Care 2014;37:2141-8
- Rosenstock J, Fonseca VA, Grass JL, et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care 2014;37:2317-25
- Reusch J, Stewart MW, Perkins CM, et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 1): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled, trial in patients with type 2 diabetes mellitus not controlled on pioglitazone ± metformin. Diabetes Obes Metab 2014;16(12):1257-64
- Weissman PN, Carr MC, Ye J. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia 2014;57(12):2475-84
- Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014;2:289-96
- Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleusediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 2014;124:4473-88
- Gier B, Butler PC, Lai CK, et al. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metabolism 2012;97:121-31
- Waser B, Blank A, Karamitopoulou E, et al. Glucagon-like-peptide-1 receptor expression and normal and diseased thyroid and pancreas. Mod Pathol 2014;10.1038/modpathol.2014.113. [Epub ahead of print]
- FDA approves Tazeum to treat type 2 diabetes. Available from: www.fda.gov/newsevents/newsroom/pressannouncements/ucm393289.htm [Last accessed at 17 September 2014]
- Center for drug evaluation and research. Available from: www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125431Orig1s000SumR.pdf [Last accessed at 8 October 2014]
- Albiglutide. Available from: https://clinicaltrials.gov/ct2/results?term=albiglutide&Search=Search [Last accessed at 30 September 2014]